Heart failure & cardiomyopathiesCohort study
Effect of heart failure pharmacotherapies in patients with heart failure with mildly reduced ejection fraction
- Retrospective cohort study
- single-centre
- multivariable adjustment
- propensity score matching
Authors' conclusion
Beta-blockers, ACEi/ARB/ARNI, and SGLT2i were independently associated with a lower risk of all-cause mortality in patients with HFmrEF, specifically when applied as combined 'HF triple therapy'.
Study context
- Population
- Consecutive patients hospitalised with HF with mildly reduced ejection fraction (HFmrEF) at one institution, 2016–2022
- Participants
- 2,109 patients
- Exposure
- Heart failure (HF) pharmacotherapies vs no treatment
- Outcome
- All-cause mortality
- Follow-up
- 30 months (median )
Main finding
As reported in the abstract
30-month all-cause mortality · 30 months
Hazard ratio (95% CI)P value
BB27.0 vs. 35.0%
0.737(0.617–0.881)
P = 0.001ACEi/ARB/ARNI25.9 vs. 37.6%
0.612(0.517–0.725)
P = 0.001SGLT2i11.9 vs. 29.5%
0.441(0.236–0.824)
P = 0.010Observational data: associations, not effects.
Further findings
Long-term all-cause mortality, combined beta-blockers (BB) + ACEi/ARB/ARNI + SGLT2i
| Comparison | HR (95% CI) | P value | |
|---|---|---|---|
| BB + ACEi/ARB/ARNI + SGLT2i | 0.456 (0.227–0.916) | P = 0.027 | |
| 0.20.5125Hazard ratio (log scale) |
HF-related rehospitalisation
- Not affected by HF pharmacotherapies
Original publication
Effect of heart failure pharmacotherapies in patients with heart failure with mildly reduced ejection fraction. Eur J Prev Cardiol. Published 21 March 2024. doi:10.1093/eurjpc/zwae121
Summarised from the published abstract; every number is checked against it